327 related articles for article (PubMed ID: 37269814)
1. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy.
Chen S; Duan H; Sun G
Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814
[TBL] [Abstract][Full Text] [Related]
2. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
3. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer.
Zhao L; Liu Y; Zhang S; Wei L; Cheng H; Wang J; Wang J
Cell Death Dis; 2022 Apr; 13(4):378. PubMed ID: 35444235
[TBL] [Abstract][Full Text] [Related]
4. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Li X; Wenes M; Romero P; Huang SC; Fendt SM; Ho PC
Nat Rev Clin Oncol; 2019 Jul; 16(7):425-441. PubMed ID: 30914826
[TBL] [Abstract][Full Text] [Related]
5. New opportunities for immunomodulation of the tumour microenvironment using chemical tools.
Su JY; Li WH; Li YM
Chem Soc Rev; 2022 Sep; 51(18):7944-7970. PubMed ID: 35996977
[TBL] [Abstract][Full Text] [Related]
6. Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy.
Sheppard AD; Lysaght J
Methods Mol Biol; 2020; 2184():233-263. PubMed ID: 32808230
[TBL] [Abstract][Full Text] [Related]
7. Lactate in the tumour microenvironment: From immune modulation to therapy.
Wang ZH; Peng WB; Zhang P; Yang XP; Zhou Q
EBioMedicine; 2021 Nov; 73():103627. PubMed ID: 34656878
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition.
Kim HJ; Cantor H; Cosmopoulos K
Trends Immunol; 2020 Oct; 41(10):948-963. PubMed ID: 32976740
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of Immune Cells in the Tumor Microenvironment.
Jung JG; Le A
Adv Exp Med Biol; 2021; 1311():173-185. PubMed ID: 34014543
[TBL] [Abstract][Full Text] [Related]
10. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
11. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity.
Zhang S; Zhang X; Yang H; Liang T; Bai X
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189022. PubMed ID: 37993001
[TBL] [Abstract][Full Text] [Related]
12. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
Mudassar F; Shen H; Cook KM; Hau E
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
[TBL] [Abstract][Full Text] [Related]
13. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
14. Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy.
Luby A; Alves-Guerra MC
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885023
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity.
Donlon NE; Power R; Hayes C; Reynolds JV; Lysaght J
Cancer Lett; 2021 Apr; 502():84-96. PubMed ID: 33450360
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumour microenvironment by tyrosine kinase inhibitor.
Tan HY; Wang N; Lam W; Guo W; Feng Y; Cheng YC
Mol Cancer; 2018 Feb; 17(1):43. PubMed ID: 29455663
[TBL] [Abstract][Full Text] [Related]
18. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.
Johnson RL; Cummings M; Thangavelu A; Theophilou G; de Jong D; Orsi NM
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944851
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
Chyuan IT; Chu CL; Hsu PN
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
[TBL] [Abstract][Full Text] [Related]
20. [Research Progress and New Immunotherapy Strategies of Tumor Microenvironment Metabolism].
Peng YM; Luo XM; Chen JY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):505-509. PubMed ID: 37248575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
